Eribulin Mesylate As Second-Line Therapy For Locally Advanced, Unresectable, Or Metastatic Pancreatic Cancer Patients

Study Overview

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

This phase II trial is studying how well E7389 works as second-line therapy in treating patients with locally advanced, unresectable, or metastatic pancreatic cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PRIMARY OBJECTIVE: I. To determine the objective response (complete and partial) to E7389 in patients with locally advanced, unresectable, or metastatic pancreatic adenocarcinoma that progressed after prior gemcitabine hydrochloride-based therapy. SECONDARY OBJECTIVE: I. To determine the antitumor activity of E7389, in terms of median survival, 1-year survival rate, response or stable disease duration, toxicity, and time to disease progression, in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive eribulin mesylate IV on days 1 and 8. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, all patients are followed at 4 weeks. Patients with complete response, partial response, or stable disease are followed every 3 months.

Adenocarcinoma of the Pancreas
Pancreatic Cancer
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

DRUG: eribulin mesylate

NCI-2009-00173
PHL-049 (OTHER_GRANT Identifier) (OTHER_GRANT: N01CM17107)
CDR0000502291 (OTHER_GRANT Identifier) (OTHER_GRANT: N01CM17107)
N01CM62203 (U.S. NIH Grant/Contract)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2006-09-29	Results First Submitted 2014-04-18	Last Update Submitted that met QC Criteria 2017-09-19
First Submitted that Met QC Criteria 2006-09-29	Results First Submitted that Met QC Criteria 2016-10-17	Last Update Posted (ACTUAL) 2017-10-20
First Posted (ACTUAL) 2006-10-03	Results First Posted 2016-12-09	Last Verified 2017-09

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Treatment (eribulin mesylate) Patients receive E7389 IV on days 1 and 8.	DRUG: eribulin mesylate Given IV

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Treatment (eribulin mesylate)

Patients receive E7389 IV on days 1 and 8.

DRUG: eribulin mesylate

Given IV

Primary Outcome Measures	Measure Description	Time Frame
Objective Response (Complete and Partial) Evaluated Using RECIST Criteria	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.	Up to 3 years

Secondary Outcome Measures	Measure Description	Time Frame
Stable Disease Rate, Evaluated Using RECIST Criteria	Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.	Up to 3 years
Median Survival Time	Estimated using the Kaplan-Meier method.	Up to 3 years
Overall Survival	Estimated using the Kaplan-Meier method.	At 6 months
Overall Survival	Estimated using the Kaplan-Meier method.	At 1 year
Median Time to Disease Progression	Estimated using the Kaplan-Meier method.	Duration of time from start of treatment until the criteria for progression are met, assessed up to 3 years
Time to Progression	Estimated using the Kaplan-Meier method. Median time to progression	At 6 months
Time to Progression	Estimated using the Kaplan-Meier method.	At 1 year
Response Duration		From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
Toxicity	Types of Gr 3 or greater adverse events that are atleast possibly related to study drug	All patients will be evaluable for toxicity from the time of their first treatment with E7389.
Objective Stable Disease Rate	Objective stable disease rate Using RECIST	Upto 3 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Histologically/cytologically confirmed pancreatic carcinoma (locally advanced, unresectable or metastatic)
measurable disease (at least 1 lesion accurately measured in at least 1 dimension (longest diameter as >20mm with conventional techniques or >10mm with spiral CT scan)
>=4 weeks from any major surgery
Up to 1 prior line of gemcitabine based systemic therapy (single agent/combination therapy) for locally advanced/metastatic disease with evidence of disease progression. Prior therapy with inhibitors of angiogenesis and/or the epidermal growth factor receptor permitted. Last chemotherapy dose >=4 weeks prior to randomization.
May have received prior 5FU (+/- folinic acid)/gemcitabine given concurrently with radiation as a "radiation sensitizer". Last chemotherapy dose >=4 weeks prior to randomization.
Prior radiation treatment >=4 weeks prior to randomization
Age >18 years.
Life expectancy >=3 months
ECOG< 2(Karnofsky-60%)
leukocytes>3,000/mcL
absolute neutrophil count>1,500/mcL
platelets>100,000/mcL
total bilirubin < 1.5 UNL
AST/ALT≤2.5x institutional ULN
creatinine within institution limits OR creatinine clearance>60mL/min/1.73m2 for patients with creatinine levels above institution limits
concurrent use of inhibitors/inducers of CYP3A4 are prohibited during the study treatment period
effects of E7389 on developing human fetus are unknown. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
Ability to understand/willingness to sign written informed consent

chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
May not be receiving other investigational agents
Known brain metastases
History of allergic reactions attributed to compounds of similar chemical or biologic composition to E7389
Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study
Pregnant women excluded because E7389 is an antitubulin agent with the potential for teratogenic/abortifacient effects
HIV-positive patients on combination antiretroviral therapy are ineligible because of potential for p PK interactions with E7389
Other active malignancies in past 5 years except for cervical carcinoma in situ and non-melanomatous skin cancer

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Malcolm Moore, University Health Network-Princess Margaret Hospital

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record